Symlin Dose Titration Mitigates Hypoglycemia, Nausea, Amylin Says
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Amylin’s recent Symlin NDA amendment shows that a dose titration regimen reduces the risks of nausea and hypoglycemia in type 1 and 2 diabetes patients, the firm reported June 15.
You may also be interested in...
Watchdog Group Revives Concerns Over Symlin Dosing Instructions
FDA's internal review of the dosing instructions for Amylin's antidiabetic Symlin likely will revisit dosing-related concerns first identified during its NDA review
Symlin Complete Response Follows "Emerging Consensus" On Hypoglycemia
Amylin expects its hypoglycemia re-analysis to mitigate FDA’s concerns about its pending antidiabetic Symlin, the company says.